Seeking Alpha

Johnson & Johnson (JNJ)

  • Dec. 19, 2012, 7:25 PM
    The FDA says that the blood thinner Pradaxa is not safe for use on patients with mechanical heart valves. A clinical trial in Europe was recently stopped because users were more likely to experience strokes, heart attacks, and blood clots forming on the mechanical heart valves than were users of the anticoagulant warfarin. There was also more bleeding after valve surgery in Pradaxa users than in warfarin users. Pradaxa's competitors include: Eliquis, from Bristol-Myers Squibb (BMY) and Pfizer (PFE), Xarelto from Johnson & Johnson (JNJ) and Coumadin, an older drug that's also from BMY.
    | Dec. 19, 2012, 7:25 PM | 4 Comments
  • Dec. 18, 2012, 6:15 PM
    The top 10 dividend-yielding stocks from the "ultimate stock pickers" at Morningstar: GSK, COP, INTC, LLY, NVS, MRK, PM, PFE, SYY, JNJ.
    | Dec. 18, 2012, 6:15 PM | 14 Comments
  • Dec. 15, 2012, 10:30 AM
    After a stretch in which it alienated the infinitely patient Warren Buffett, Johnson & Johnson (JNJ) may be poised for strong performance, writes Andrew Bary. While the Oracle was selling, the Street was starting to warm up to the company. Revenue growth is improving, and the dividend - the stock yields 3.45% - should continue to grow at 8% annually for years. Underweight institutional investors might soon find themselves needing to buy.
    | Dec. 15, 2012, 10:30 AM | 5 Comments
  • Dec. 10, 2012, 2:30 PM
    Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceutical days the FDA has approved a broader indication for Zytiga. The drug, in combination with prednisone, may now be used earlier in the treatment continuum, before the use of chemotherapy. Zytiga also received a positive opinion for an expanded indication from the EMA and is under review by other health authorities worldwide.
    | Dec. 10, 2012, 2:30 PM | 1 Comment
  • Dec. 9, 2012, 3:42 AM
    Pharmacyclics's (PCYC) and J&J's (JNJ) ibrutinib for chronic lymphocytic leukemia slowed the progression of the blood cancer when used alone and with Roche's Rituxan in early to mid-stage trials. On its own, ibrutinib stopped the disease worsening for 26 months in 96% of untreated patients and in 75% of those that had relapsed or were at risk of doing so. (PR)
    | Dec. 9, 2012, 3:42 AM | Comment!
  • Dec. 9, 2012, 3:28 AM
    Pfizer's (PFE) and Bristol-Myers Squibb's (BMY) Eliquis blood thinner cut the risk of clots in veins and lungs, and death, by 81% compared with a placebo in major year-long trial. Bleeding was also low. BMY could rack up sales of $4.18B by 2018 if Eliquis is approved - the drug would compete with warfarin, Xarelto from Bayer and J&J (JNJ), and Pradaxa from Boehringer Ingelheim. (PR)
    | Dec. 9, 2012, 3:28 AM | 5 Comments
  • Dec. 4, 2012, 11:42 AM
    Many U.S. firms are cash rich abroad but cash poor at home, and the SEC worries they aren’t presenting investors with an honest appraisal of their liquidity. “That doesn’t mean they could suddenly run out of money to pay their bills," WSJ's Kate Linebaugh writes. "But it does mean there could be unseen limits on their ability to pay dividends and buy back shares."
    | Dec. 4, 2012, 11:42 AM | 37 Comments
  • Dec. 4, 2012, 9:54 AM
    An Australian judge has approved a settlement between J&J (JNJ) and patients who received dodgy knee implants, clearing the way for the company to  pay compensation of at least A$30,000 ($31,000) per case. J&J recalled the implant in 2009 following reports of defects. Over 5,070 implants were used in Australia, while the number of inquiries about the proposed deal is over 430.
    | Dec. 4, 2012, 9:54 AM | Comment!
  • Dec. 4, 2012, 8:13 AM
    An appeals court ruling yesterday that dismissed the conviction of a sales rep who sold a drug for non-FDA approved uses could have major ramifications for pharmaceutical companies, which have paid billions in fines for doing just that. Two out of three judges agreed with Alfred Caronia that his rights to free speech were violated. The government is expected to appeal the case, which could find its way to the Supreme Court.
    | Dec. 4, 2012, 8:13 AM | 9 Comments
  • Nov. 30, 2012, 9:17 AM
    Johnson & Johnson (JNJ) CEO Alex Gorsky is elected Chairman of the Board. Current chairman Bill Weldon will step down on Dec. 28. Weldon was also CEO before being replaced by Gorsky earlier this year. (PR)
    | Nov. 30, 2012, 9:17 AM | Comment!
  • Nov. 29, 2012, 9:38 AM
    J&J (JNJ) won't enforce its patents on its HIV/AIDS drug Prezista in sub-Saharan Africa and other poor countries, allowing generic pharmaceutical companies to manufacture cheap versions of the drug as long as the quality remains high. However, J&J won't share its IP in the new Medicines Patent Pool, saying it wants "to reserve the right to reinforce patents."
    | Nov. 29, 2012, 9:38 AM | Comment!
  • Nov. 26, 2012, 10:03 AM
    The FDA says J&J's (JNJ -0.3%) bedaquiline for treating a drug-resistant form of tuberculosis appears to be "safe and well-tolerated," although the highest dose could cause a small change in the heart's rhythm. J&J is seeking accelerated, temporary approval of bedaquiline; an FDA advisory committee is due to review the drug on Wednesday.
    | Nov. 26, 2012, 10:03 AM | Comment!
  • Nov. 20, 2012, 2:15 PM
    Apple (AAPL) tops the 10 high-conviction purchases Morningstar's "ultimate stock pickers" like right now. With Apple looking at a strong iPhone 5 launch into the holiday season, the current share price does not fully reflect the value it should be able to generate for shareholders in the near- to medium-term. The others: JNJ, JPM, CHRW, COP, CME, ACN, RIMM, NLY, TROX.
    | Nov. 20, 2012, 2:15 PM | 19 Comments
  • Nov. 19, 2012, 4:09 PM
    Johnson & Johnson (JNJ -0.1%) finishes the day relatively flat, despite saying earlier that its Janssen Pharmaceuticals unit has been granted a positive opinion by the CHMP of the European Medicines Agency recommending approval of its prostate cancer treatment Zytiga.
    | Nov. 19, 2012, 4:09 PM | Comment!
  • Nov. 16, 2012, 5:14 AM
    Schiff Nutrition (SHF) shares surged 30% to $44.10 in post-market trading after it became the subject of a bidding war. Reckitt Benckiser (RBGPF.PK) has offered $1.4B, or $42/share, to acquire Schiff, topping a $1.2B proposal from Bayer (BAYZF.PK). Buying Schiff would enable Reckitt to enter the $30B market for vitamins and supplements, a temptation that analysts think could prompt J&J (JNJ) into making a bid as well.
    | Nov. 16, 2012, 5:14 AM | Comment!
  • Nov. 15, 2012, 5:56 PM
    Johnson & Johnson (JNJ), Merck (MRK) and Eli Lilly (LLY) are collaborating in a global project to create a database aimed at getting patient tests of experimental drugs up and running more quickly and efficiently, which would eventually mean new medicines will get approved and reach patients sooner. The database will give drug companies working on experimental drugs a one-time approval process and drug makers a big pool of ready, qualified scientists with known expertise.
    | Nov. 15, 2012, 5:56 PM | Comment!
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.